secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001193125-22-151011
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Q1 net loss $23M; MGTA-117 shows target binding and rapid clearance at lowest dose
--------------------------------------------------------------------------------

- Net loss of $23.0M for Q1 2022 vs. $17.5M in Q1 2021; R&D expenses rose to $16.5M from $11.7M.
- Cash, equivalents and marketable securities $156.6M as of Mar 31, 2022; expected to fund operations into Q2 2024.
- Phase 1/2 MGTA-117 Cohort 1 data: target binding on CD117+ cells, rapid drug clearance within 48 hours, no serious drug-related AEs; dose escalation to Cohort 2 (0.04 mg/kg) underway.
- One patient with low blast burden showed ~83% reduction of bone marrow blasts at day 14; supports planned transition to transplant-eligible AML patients.
- IND-enabling studies for CD45-ADC ongoing; key toxicology results expected 2H 2022. MGTA-145 sickle cell trial startup progressing; initial data expected 2H 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522151011/0001193125-22-151011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522151011/d264834d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-151011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer